<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
        {font-family:"Cambria Math";
        panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:Tahoma;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0cm;
        margin-bottom:.0001pt;
        font-size:12.0pt;
        font-family:"Times New Roman","serif";}
h1
        {mso-style-priority:9;
        mso-style-link:"Heading 1 Char";
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:24.0pt;
        font-family:"Times New Roman","serif";
        font-weight:bold;}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:blue;
        text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
        {mso-style-priority:99;
        color:purple;
        text-decoration:underline;}
p
        {mso-style-priority:99;
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:12.0pt;
        font-family:"Times New Roman","serif";}
span.Heading1Char
        {mso-style-name:"Heading 1 Char";
        mso-style-priority:9;
        mso-style-link:"Heading 1";
        font-family:"Cambria","serif";
        color:#365F91;
        font-weight:bold;}
span.EmailStyle19
        {mso-style-type:personal-reply;
        font-family:"Calibri","sans-serif";
        color:#1F497D;}
.MsoChpDefault
        {mso-style-type:export-only;}
@page WordSection1
        {size:612.0pt 792.0pt;
        margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
        {page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>Hi all: <o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>See link below to interesting article.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>Glen<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'><br><b>Sent:</b> May 24, 2017 4:36 PM<br><b>To:</b> FYI Prostate Info<br><b>Subject:</b> FYI From healio.com Topic:Single-fraction, high-dose brachytherapy may be viable for localized prost<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><h1>Single-fraction, high-dose brachytherapy may be viable for localized prostate cancer<o:p></o:p></h1><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=MsoNormal>Follow Link<o:p></o:p></p></div><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=MsoNormal><a href="http://www.healio.com/hematology-oncology/prostate-cancer/news/online/%7B6175477d-cb93-401d-8d0f-8c8263b0d3d3%7D/single-fraction-high-dose-brachytherapy-may-be-viable-for-localized-prostate-cancer?page=2">http://www.healio.com/hematology-oncology/prostate-cancer/news/online/%7B6175477d-cb93-401d-8d0f-8c8263b0d3d3%7D/single-fraction-high-dose-brachytherapy-may-be-viable-for-localized-prostate-cancer?page=2</a><o:p></o:p></p></div></div><p class=MsoNormal>-- <br>You received this message because you are subscribed to the Google Groups "FYI Prostate Info" group.<br>To unsubscribe from this group and stop receiving emails from it, send an email to <a href="mailto:fyi-prostate-info+unsubscribe@googlegroups.com">fyi-prostate-info+unsubscribe@googlegroups.com</a>.<br>To post to this group, send email to <a href="mailto:fyi-prostate-info@googlegroups.com">fyi-prostate-info@googlegroups.com</a>.<br>To view this discussion on the web visit <a href="https://groups.google.com/d/msgid/fyi-prostate-info/05f9fab0-cca1-4531-b90f-ab0e0447d71d%40googlegroups.com?utm_medium=email&utm_source=footer">https://groups.google.com/d/msgid/fyi-prostate-info/05f9fab0-cca1-4531-b90f-ab0e0447d71d%40googlegroups.com</a>.<br>For more options, visit <a href="https://groups.google.com/d/optout">https://groups.google.com/d/optout</a>.<o:p></o:p></p></div></body></html>